TOP STORIES
oncology

ESMO Virtual 2020

Friday 18th - Tuesday 22nd September 2020
GU

Watch now: ESMO 2020: GU Highlights through an Australian lens

If you didn’t get the chance to join our expert panel in discussing the highlights from ESMO 2020 GI clinical tracks and what they mean for clinical practice in Australia, you can now watch the webcast on demand. ...

If you didn’t get the chance to join our expert panel in discussing the highlights from ESMO 2020 GI clinical...
Medicines

Drugging the undruggable? KRAS inhibitor shows early promise

Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A phase 1 trial of sotorasib in 129 patients - including Australians - with mainly non-small cell lung cancer (NSCLC) and...

Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A...
Breast

New first-in-class treatment option for triple negative breast cancer

Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according to discussion at ESMO 2020. A phase 3 study, presented at the ESMO Virtual Congress 2020, randomised 529 women to either...

Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according...